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AbstrACt
Introduction Left ventricular diastolic dysfunction (LVDD) 
is a common condition in both sexes that may deteriorate 
into heart failure (HF) with preserved ejection fraction 
(pEF), although this seems to happen more often in women 
than in men. Both LVDD and HFpEF often go unrecognised, 
necessitating the discovery of biomarkers that aid both the 
identification of individuals with LVDD at risk of developing 
HF and identification of individuals most likely to benefit 
from treatment.
Methods and analysis HELPFul is an ongoing case-
cohort study at a Dutch cardiology outpatient clinic 
enrolling patients aged 45 years and older without 
history of cardiovascular disease, who were referred 
by the general practitioner for cardiac evaluation. We 
included a random sample of patients and enriched 
the cohort with cases (defined as an E/e’ ≥8 measured 
with echocardiography). Information about medical 
history, cardiovascular risk factors, electrocardiography, 
echocardiography, exercise test performance, common 
carotid intima-media thickness measurement and 
standard cardiovascular biomarkers was obtained from 
the routine care data collected by the cardiology outpatient 
clinic. Study procedure consists of extensive venous blood 
collection for biobanking and additional standardised 
questionnaires. Follow-up will consist of standardised 
questionnaires by mail and linkage to regional and national 
registries. We will perform cardiac magnetic resonance 
imaging and coronary CT angiography in a subgroup of 
patients to investigate the extent of macrovascular and 
microvascular coronary disease.
Ethics and dissemination The study protocol was 
approved by the Institutional Review Board of the 
University Medical Center Utrecht. Results will be 
disseminated through national and international 
conferences and in peer-reviewed journals in 
cardiovascular disease.
trial registration NTR6016;Pre-results.
IntroduCtIon
Cardiac disease is a leading cause of morbidity 
and mortality in industrialised societies.1 
There is an urgent need for early detection of 
structural and functional cardiac abnormali-
ties before coronary events occur or before 
heart failure (HF) develops. HF has a poor 
prognosis in both sexes, with data from the 
strengths and limitations of this study
 ► Case-cohort study in novel setting: patients at risk 
of cardiovascular disease at a Dutch cardiology out-
patient clinic positioned between the general practi-
tioner and hospitals.
 ► Venous blood sampling of multiple types of plasma 
as well as serum, cells and DNA for biobanking.
 ► Designed to accommodate the changing definitions 
of left ventricular diastolic dysfunction (LVDD) and 
(subtypes of) heart failure (HF).
 ► Initial results show a high prevalence of hyperten-
sion, but low prevalence of chronic inflammatory 
comorbidities, such as diabetes mellitus and over-
weight, for a study investigating LVDD and HF.
 ► No information on reason for referral by the general 
practitioner.
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Netherlands showing high mortality rates 30 days, 1 year 
and 5 years after first hospital admission for HF (13%, 
32% and 64% for men and 14%, 33% and 66% for 
women, respectively). Mortality rates increased consid-
erably with age, in both men and women, for example, 
1-year mortality was 10.5% in women aged 25–54 years 
and increased to 46.1% in those aged 85 years and older.2 
This is alarming because HF is common among elderly 
in the general population with a median prevalence rate 
of 11.8%.2 3 HF can be divided into two types: HF with 
preserved ejection fraction (HFpEF) with a left ventric-
ular ejection fraction (LVEF) >50% and HF with reduced 
ejection fraction (HFrEF) with an LVEF <40%.4 HF is 
characterised by insufficient pumping of the heart or 
close to sufficient at the price of increased left ventric-
ular (LV) filling pressures in rest or during exercise.5 
Generally HFpEF is characterised by increased LV filling 
pressures that are caused by concentric remodelling 
and reduced filling, whereas HFrEF is characterised by a 
lack of contractility and eccentric remodelling.6 HFpEF 
is rising in prevalence, but its precursor left ventricular 
diastolic dysfunction (LVDD) is even more prevalent and 
can also eventually lead to HFrEF or HF with mid-range 
ejection fraction (HFmrEF) with an LVEF 40%–49%.7 
Important risk factors for developing LVDD and even-
tually HFpEF are hypertension, overweight, diabetes 
mellitus and previous ischaemic heart disease.8 Within 
4–5 years 12%–25% of patients with established LVDD 
progress to symptomatic HFpEF.9–11 However, there is 
still a knowledge gap as to who will progress from LVDD 
to HFpEF (or other types of HF), and which drivers are 
involved in this deterioration.12 
Interestingly, the prevalence of LVDD is similar in 
men and women,13 14 but women with LVDD seem prone 
to more often develop HFpEF, while men more often 
develop HFrEF.15–19 This sex difference in progression 
from LVDD to HFpEF is currently poorly understood and 
warrants closer attention, especially in the view of early 
identification of patients at risk for worsening LVDD.20 21 
Sex differences in underlying mechanisms may partially 
explain the observed difference in HFpEF prevalence. 
Women more often present with coronary microvascular 
dysfunction (CMD).22 CMD may lead to myocardial stiff-
ening and LV filling problems, both features of LVDD 
and HFpEF. Men more often present with pronounced 
coronary macrovascular disease, a hallmark of HFrEF.22
To expand the current knowledge about LVDD and 
HFpEF, it is important to better understand this under-
lying heterogeneity.23 One promising method to differen-
tiate heterogeneous groups within HFpEF is by detailed 
‘mapping’ of the different phenotypes using both clinical 
information and biomarkers. Ideally, these biomarkers 
reflect different pathophysiological processes at the tissue 
level. Another method may be the application of ‘omics’ 
studies.24 Identification of patients prone to progression 
of LVDD to HFpEF may aid the development of new treat-
ment options for patients with HFpEF. While effective 
treatment options are available for HFrEF and some show 
effectiveness in patients with HFmrEF,25 26 these treat-
ments are ineffective for patients with HFpEF,27 although 
spironolactone might yet prove to be beneficial.28–30 
At the moment, only aggressive preventive treatment 
focused on managing hypertension, overweight, diabetes 
mellitus and a more active lifestyle seem to be effective in 
reverting or slowing the progression of LVDD to HFpEF.7
The aim of the HELPFul study is to discover sex-spe-
cific biomarkers for LVDD and HFpEF using several 
approaches such as multimarker panels and ‘omics’ 
studies in combination with extensive additional coro-
nary phenotyping with cardiac magnetic resonance 
(CMR) imaging and coronary CT angiography (CCTA) 
in high-risk individuals.
MEthods And AnAlysIs
study design
HELPFul is a single-centre, prospective, case-cohort study 
conducted at a cardiology outpatient clinic in Utrecht, the 
Netherlands. All patients aged 45 years and older, without 
previous cardiac interventions or congenital heart disease, 
who are referred by the general practitioner (GP) to this 
outpatient clinic are eligible for inclusion. On three of the 
four inclusion days, only patients with elevated LV filling 
pressures, defined as an E/e’ ≥8.0 are eligible for inclu-
sion. On the fourth day, 25% of all patients attending that 
day are invited to participate regardless of their echocar-
diography results (box 1). The case-cohort design results 
in a group of ‘cases’ that have slightly elevated LV filling 
pressures, of whom a percentage may eventually deterio-
rate in diastolic function. Part of the patients in the case 
group may also already have LVDD. The random sample 
will reflect the distribution of exposure and also serve as a 
pool for the selection of healthy controls. With a case-co-
hort design the distribution of LVDD and HFpEF in the 
source population is accurately reflected in the random 
sample, while simultaneously creating a pool for the 
selection of controls.31 A flow chart of the study design 
and procedures is presented in online supplemental 
figure S1.
box 1 Inclusion and exclusion criteria for the hElPFul 
study
Inclusion: a patient must meet criteria 1, 2 and either 3 or 4Inclusion: a 
patient must meet criteria 1, 2 and either 3 or 4
1. Age ≥45 years. 
2. Written informed consent.
3. E/e’ ≥8.0 (selectively for those included as a case).
4. Consultation on a random sample day.
Exclusion: a patient cannot be included in case of any of the criteria 
belowExclusion: a patient cannot be included in case of any of the cri-
teria below
1. Any past cardiac intervention.
2. Congenital heart disease.
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study population
Participants are enrolled at the Cardiology Center Utrecht 
(CCU), one of the outpatient clinics of the Cardiology 
Center Netherlands. Recruitment of participants started 
19 September 2016 and will continue until July 2019. CCU 
covers the area of the city of Utrecht and neighbouring 
cities and towns, and on average receives 10–20 newly 
referred patients per day. The study population comprises 
adults in the Netherlands aged 45 years and older referred 
for cardiac evaluation by their GP. Only patients without 
previous cardiac surgery, a previous cardiac intervention 
or congenital heart disease are eligible for inclusion. The 
following cardiac surgical procedures or interventions are 
considered exclusion criteria: angioplasty, bypass surgery, 
heart valve surgery or intervention, implantable cardiac 
defibrillator and/or cardiac resynchronisation therapy, 
radiofrequency ablation, LV assist device, heart trans-
plantation and pacemaker. Patients referred for preoper-
ative screening or by other specialists than the GP, such 
as insurance physicians or company physicians, are also 
excluded from participation.
rationale for study setting
The CCU cardiology outpatient clinic is positioned 
between the GP and the hospital and is intended for 
quick referral and fast diagnostics to serve the GP, which 
results in a population at this centre with fewer symptoms 
and lower cardiovascular disease risk than the population 
often seen in a similar setting at the hospital. Within this 
population, we expect large variety in diastolic function, 
ranging from normal diastolic function to definite LVDD 
and HFpEF. HFpEF is a syndrome that often presents 
with intermittent complaints of dyspnoea and/or other 
less typical symptoms, which can be difficult to detect, 
especially in elderly patients in the community. GPs are 
usually the first clinicians who see these patients with 
unexplained symptoms. Due to the efficient workflow 
of the cardiac outpatient clinic it is possible to perform 
this diagnostic workup for 10–20 new patients each day. 
There is no waiting list and patients can often be seen 
within days, even if their complaints are not urgent. This 
makes referral to this cardiac outpatient clinic a fast and 
convenient option for the GP. Due to this unique setting 
the source population of the HELPFul study is different 
from patients who are referred to the hospital. It there-
fore provides a unique opportunity to study risk factors 
and biomarker levels in patients who have not developed 
LVDD or HFpEF yet, or are still in the early stages of 
LVDD or HFpEF.
study end points
The primary end point is a diagnosis of LVDD or HFpEF. 
The primary end point is adjudicated by a panel of three 
experts based on all available diagnostic information and 
the current recommendations from the 2016 European 
Society of Cardiology (ESC) guidelines for the diagnosis 
and treatment of acute and chronic heart failure.5 32–35 
The expert panel will comprise two of four available 
cardiologists (MJMC, AT, RM, LPS) and a GP specialised 
in HF (FR). Adjudicating the end point by an expert 
panel is considered the preferred method as a sufficiently 
reliable reference standard for HFpEF is lacking.36 If the 
diagnostic criteria for LVDD or HFpEF change over time, 
we will incorporate these new criteria in the classification 
of LVDD or HFpEF in the HELPFul study population.
Secondary end points are (i) hospitalisation for HF, 
(ii) a composite end point of cardiovascular death (due 
to myocardial infarction, stroke, HF, peripheral arterial 
disease and sudden death of unspecified cause) and (iii) 
all-cause mortality.
definition of lVdd/hFpEF
HFpEF is initially defined according to recommendations 
of the 2016 ESC guidelines for the diagnosis and treatment 
of acute and chronic heart failure (table 1). Participants 
with (i) symptoms or signs typical of HF and/or brain 
natriuretic peptide (BNP) >35 pg/mL, (ii) in combination 
with an LVEF >50% and (iii) objective echocardiographic 
Table 1 Definition of subtypes of HF*
Type of HF HFrEF HFmREF HFpEF
Criteria 
  1 Symptoms and/or signs† Symptoms and/or signs† Symptoms and/or signs†
  2 LVEF <40% LVEF 40%–49% LVEF≥50%
  3 – 1. Elevated levels of BNP‡
2. At least one additional criterion:
a. Relevant structural heart disease 
(LVH and/or LA enlargement),
b. Diastolic dysfunction
1. Elevated levels of BNP‡
2. At least one additional criterion:
a. Relevant structural heart disease 
(LVH and/or LA enlargement),
b. Diastolic dysfunction
*Adapted from 2016 ESC guidelines for acute and chronic heart failure.5
†Signs may not be present in early stage of HF (especially in HFpEF) and in patients treated with diuretics.
‡BNP>35 pg/mL.
BNP, B-type natriuretic peptide; ESC, European Society of Cardiology; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; 
HFmREF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; LA, left atrial; LVH, left ventricular 
hypertrophy.
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evidence of LVDD will be classified as having HFpEF.5 
The presence of these criteria but with an LVEF between 
40% and 49% or an LVEF <40% will result in participants 
being classified as having HFmrEF and HFrEF, respec-
tively (table 1). LVDD is defined as E/e’ ratio >13 or E/e’ 
between 8 and 13 with other structural abnormalities, 
such as left atrial volume index (LAVi) >34 mL/m2, or 
left ventricular mass index (LVMi) >95 g/m2 for women 
and >115 g/m2 for men and/or functional abnormalities, 
such as e’ lateral <10 m/s or e’ septal <7 m/s or tricuspid 
regurgitation (TR) velocity >2.8 m/s.5
standard care measurements at enrolment
Standard care measurements consist of history taking, 
physical examination, ECG (Welch Allyn Cardioperfect 
Pro recorder), laboratory blood measurements (Roche 
Reflotron Sprint system), an exercise test on a watt bike 
(Lode Corival Eccentric) with simultaneous blood pres-
sure measurements (Medtronic BL-6 Compact) and ECG 
recordings (Welch Allyn Cardioperfect recorder) and 
transthoracic echocardiography (with a General Electric 
Vivid E6 or E7 cardiovascular echocardiography device). 
In addition, comorbidities and current medication use will 
be registered. Physical examination includes measuring 
height and weight, blood pressure (two readings at least 
on a Microlife WatchBP), pulse rate and calculation of 
the respiratory rate. A standard 12-lead ECG (Welch Allyn 
Cardioperfect Pro recorder) will be recorded in supine 
position and interpreted by a cardiologist. The standard 
laboratory test returns plasma and serum levels of potas-
sium, glucose, haemoglobin, creatinine, total cholesterol, 
low-density lipoprotein, high-density lipoprotein and 
triglycerides.
Echocardiography
Comprehensive transthoracic echocardiographic exam-
inations were performed by trained sonographers and 
interpreted by a cardiologist in accordance with the Euro-
pean Association of Cardiovascular Imaging 2016 recom-
mendations for chamber quantification.37 The LVEF 
was assessed quantitatively (Teichholz), or semi-quanti-
tatively (eye-balling). Multiple diastolic parameters were 
measured, including pulsed-wave Doppler of the mitral 
and pulmonary venous inflow and tissue Doppler imaging 
of the mitral annulus motion. The ratio of peak early (E) 
diastolic filling velocity to peak atrial (A) contraction 
filling velocity was calculated to derive the E/A ratio. The 
early diastolic mitral annular recoil velocity (e’) was deter-
mined at both the septal and lateral wall. The E/e’ ratio 
was calculated by dividing E with the average of septal and 
lateral e’. LAVi was derived from tracing the left atrium 
during maximal atrial filling in the apical two-chamber 
and apical four-chamber views and subsequently indexing 
by body surface area (BSA). LVMi was calculated according 
to the formula validated by Devereux and subsequently 
indexed by BSA.38 The sonographers assessed TR in the 
parasternal right ventricular inflow, parasternal short-
axis and apical four-chamber views. A minimum of five 
sequential complexes were recorded. The peak velocity 
of the TR signal was measured with continuous-wave 
Doppler and the systolic pulmonary artery pressure was 
calculated with the modified Bernoulli's equation.39
Cardiologist consult
The standard care protocol is for the CCU cardiologist to 
perform an assessment of all information that is collected 
during diagnostic workup. The cardiologist may wish to 
extend beyond the standard diagnostic workup proce-
dure when there is a medical indication to do so. Addi-
tional information on symptoms may be collected, or 
the cardiologist may perform additional physical exam-
inations in accordance with the appropriate guidelines.5 
All data collected during the standard care pathway is 
recorded in the electronic health database of CCU and 
will be extracted for HELPFul patients. Aside from the 
data collected during diagnostic workup, the electronic 
health database of CCU may contain information on 
follow-up visits and on results of procedures performed at 
other locations than CCU.
specific hElPFul measurements
Eligible patients are invited to participate in the HELPFul 
study by their CCU cardiologist at the end of the visit. 
After obtaining informed consent, a study physician or a 
trained research nurse takes a detailed questionnaire of 
the patient at the baseline visit. Data were collected on 
symptoms (including questions adapted from the Minne-
sota Living with Heart Failure questionnaire, New York 
Heart Association classification and Medical Research 
Council dyspnoea scale), cardiovascular risk factors, 
general and cardiovascular medical history, family history 
for cardiovascular events (positive if a first-degree relative 
had a cardiovascular event at age 65 years or younger), 
pregnancy history and menopausal status and medication 
use.
study-specific blood sampling
Approximately 70 mL of venous blood is collected at 
baseline immediately after obtaining informed consent. 
After ultracentrifugation, serum, EDTA, citrate and sodi-
um-heparin plasma are aliquoted and frozen at −80°C. 
Peripheral blood mononuclear cells (PBMCs) are isolated 
from EDTA blood and stored in a CoolCell freezing 
container to ensure freezing at a standardised controlled 
rate of −1 °C/min cell in a −80°C freezer. Whole blood 
EDTA aliquots are frozen at −80°C for the purpose of 
storing genetic material for genome analyses. All samples 
are frozen within 2 hours after the blood samples were 
taken by venipuncture. Both blood and cell samples are 
transported to the Central BioBank of the University 
Medical Center Utrecht (UMCU) on a weekly basis for 
long-term storage of aliquoted samples in −80°C freezers 
and of PBMC vials in liquid nitrogen tanks. One 2.5 mL 
EDTA plasma tube is transported to the clinical chemistry 
department of the UMCU for haematological analysis by 
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an Abbott CELL-DYN Sapphire in order to obtain white 
blood cell counts and differentials.
Plasma biomarkers
BNP and high-sensitivity troponin-I (hs-TnI) are 
measured in plasma of every participant as part of the 
research protocol. Hs-TnI and BNP are measured using 
the appropriate assay on the ARCHITECT i2000 analyzer 
(Abbott Park, Chicago, Illinois, USA).
Assessment for microvascular disease
As part of a recent (2018) amendment of the HELPFul 
study, patients presenting at CCU with complaints of 
chest pain are invited for additional CMR and CCTA. 
The aim of this project is to improve the phenotyping of 
the HELPFul population by assessing the prevalence of 
both (non-) obstructive coronary artery disease (CAD) 
and CMD. This extensive phenotyping may further 
aid in identification of subgroups that can be used for 
biomarker discovery studies.
hElPFul study follow-up
All participants will be followed up for occurrence of 
any cardiac event (fatal and non-fatal myocardial infarc-
tion, proven unstable angina, coronary revascularisation, 
hospitalisation for HF, stroke, peripheral arterial disease, 
sudden death of unspecified cause and death from any 
cause) by means of:
1. linkage with regional (Julius GPs Network)40 and na-
tional registries (National Hospital Discharge Registry 
and Statistics Netherlands (ie, National Causes of 
Death Registry))41;
2. questionnaires sent through email or letter 2 years af-
ter enrolment in HELPFul, after which a yearly ques-
tionnaire will be sent. The questionnaires will enquire 
after status of symptoms of cardiovascular disease and 
specifically of heart failure and hospitalisation for car-
diac disease.
Case-control selection within the case-cohort
For the case-cohort, we consider cases to be patients with 
echocardiographic-defined E/e’ ≥8. Cohort refers to 
the total population sample (which could also include 
patients with E/e’ ≥8). In this way, we create a case-cohort 
design. For a nested diagnostic case-control study, we take 
samples from this case-cohort study in which the cases 
are patients with HFpEF, and controls (no HFpEF) are 
sampled from the cohort. For the power calculations, we 
use the 'Harrell's rule of thumb' applicable to diagnostic 
research. For the aforementioned calculation, we specu-
late that around 15% of the patients will be diagnosed 
with HFpEF; the true cases for the nested case-control 
design. Thus, we can evaluate one diagnostic predictor 
in multivariable logistic regression analysis per 10 HFpEF 
cases. As we aim to analyse at least 15 determinants/
biomarkers, we therefore would need at least 150 patients 
with HFpEF. Hence, we require the inclusion of around 
1000 patients in total.
statistical analyses
Descriptive data will be presented as frequencies with 
proportions for categorical variables and either as means 
with corresponding SD or medians with corresponding 
IQR for continuous variables depending on the distri-
bution. We will use the appropriate statistical tests for 
differences at baseline, such as Pearson's Χ2 test for 
frequencies, Mann-Whitney U test for non-normally 
distributed continuous variables and Student’s t-test for 
normally distributed variables. In case of possible interac-
tion of sex, interaction terms will be created for sex and 
for each variable of interest. The interaction terms will 
then be tested for significance using logistic regression 
models.
Logistic regression will be used to analyse the associ-
ation of various determinants with LVDD and HFpEF 
status at baseline. Survival analyses will be used to evaluate 
the relationship between baseline determinants and the 
primary and secondary study outcomes. All models will be 
adjusted for suspected confounders. All data analyses will 
be performed using appropriate statistics software.
data analysis prediction algorithm
We will develop a prediction model using state-of-the-art 
methodology as described in the Transparent Reporting 
of multivariable prediction model for Individual Prog-
nosis Or Diagnosis (TRIPOD) statement.42 Missing data 
will be imputed to minimise bias and loss of precision. 
The choice of imputation technique will depend on the 
extent and type of missing data. The linearity assumption 
will be tested using restricted cubic splines and trans-
formations will be applied where necessary. A backstep 
model will be used to eliminate redundant predictors, 
using the likelihood ratio test with a p value of 0.157 
(equal to Akaike’s Information Criterion for predictors 
with 1 df). Eliminating redundant predictors reduces the 
risk of overfitting the prediction model and makes the 
model easier to use.
The discrimination and calibration of both models will 
be compared between the overall and final (reduced) 
prediction model to evaluate their performance. Discrim-
ination is defined as the ability of the model to distinguish 
between patients who have LVDD and/or HFpEF from 
those who do not have the outcome and is quantified 
with the area under the curve (AUC) of a receiver oper-
ating characteristic plot. Calibration refers to the agree-
ment between the predicted absolute risks of HFpEF 
being present and the observed HFpEF frequencies. This 
is expressed by comparing the observed incidence of 
HFpEF per predicted risk category.
Prediction models are known for overestimated regres-
sion coefficients, which result in too extreme (optimistic) 
predictions when applied in new patients. Therefore, 
we will (internally) validate our model with bootstrap-
ping techniques where in each bootstrap sample the 
entire modelling process (including the variable selec-
tion process) is repeated. The regression coefficients 
of the final model are then adjusted for overfitting 
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by multiplying it with the estimated shrinkage factor, 
yielded from the bootstrap. The bootstrap procedure is 
also used to correct the AUC for overfitting, which can 
be considered as an estimate of discriminative ability 
that is expected in future patients. These analyses will be 
performed using the appropriate R version.
dIsCussIon
The HELPFul study is currently recruiting men and 
women at a cardiology outpatient clinic with the double 
aim of studying LVDD and HFpEF and providing suffi-
cient power for sex-stratified biomarker research. We 
expect the prevalence of LVDD and HFpEF in the 
HELPFul study to be similar to the prevalence in other 
studies that screened patients at the GP practice.3 34 43 44 
Biomarkers panels derived from discoveries made in the 
HELPFul study may help to direct screening both at the 
GP practice and (outpatient) cardiology clinics.
To the best of our knowledge, the evidence on (predic-
tion of) LVDD deterioration is rather limited. While 
information is available on risk factors for and biomarkers 
associated with development of HFpEF,9 10 45 the few 
studies investigating the development of LVDD did not 
include biomarkers.9 11 46 These studies have shown that 
diastolic function deteriorates in around 25% of patients 
with LVDD over the course of 5 years9 11 and that LVDD 
is an independent risk factor for development of HF.9 46 
Preventing the development of LVDD in this population 
is therefore highly relevant, because it may prevent many 
new cases of HF as well. However, current international 
guidelines on HF do not provide any recommendations 
on early detection of LVDD and subsequent preven-
tion of HFpEF. As a consequence, current treatment is 
focused on reduction of symptoms and management 
of risk factors in patients with LVDD who have already 
progressed to HFpEF. However, it is generally acknowl-
edged that (drug) interventions could be more effective 
in the very early phases of HFpEF or LVDD underscoring 
the relevance of early biomarkers and mechanistic 
insight.7
One of the aims of the HELPFul study is to fill this 
knowledge gap by focusing on biomarkers that may 
aid the prediction of LVDD deterioration. We will use 
follow-up echocardiography measurements to investigate 
drivers associated with progression of LVDD and develop-
ment of HFpEF in the participants of the HELPFul study. 
In addition, linkage to nationwide hospitalisation regis-
ters and death registers will enable the assessment of the 
clinical consequences of LVDD and HFpEF.
To investigate the possible connection between micro-
vascular disease and LVDD and HFpEF, the prevalence 
of (non-)obstructive CAD and CMD will be assessed 
using CMR and CCTA imaging. A meta-analysis of inter-
national variations in angina prevalence across 31 coun-
tries showed a slightly higher prevalence of angina in 
women with a pooled sex ratio of 1.20.47 Other studies 
have suggested that this could be driven by CMD instead 
of obstructive CAD of the epicardial vessels.48 49 Further-
more, in a cohort of women with chest pain suspected for 
obstructive CAD, those who were hospitalised for HF at 
6-year follow-up suffered predominantly from HFpEF.50
The HELPFul study is designed to accommodate 
changes in the definitions of LVDD and HFpEF, HFrEF 
and HFmrEF, which have occurred frequently over the 
past 10 years. At the moment, multiple guidelines for 
HF5 51 provide different criteria and cut-offs for LVDD 
and HFpEF.52 53 This has resulted in varying recommen-
dations over the last decades, which hampers the compar-
ison of diagnostic studies of LVDD and HFpEF.16
limitations
1. The cases as defined in the study design are not nec-
essarily patients with LVDD or HFpEF by current di-
agnostic criteria, but were selected for having slightly 
elevated LV filling pressures on echocardiography. 
As explained in the discussion, there is a knowledge 
gap on which patients with a possible early form of 
LVDD will eventually progress towards actual LVDD. 
Therefore, we consider sampling these patients to in-
vestigate biomarker levels and risk factors involved in 
progression to LVDD of high value. However, we are 
sampling relatively many participants with no defini-
tive diagnosis of LVDD or HFpEF by current diagnos-
tic criteria. However, this will predominantly lead to a 
lower efficiency for selection of patients with LVDD or 
HFpEF, whereas it does provide the opportunity to ef-
ficiently study patients most at risk of eventually devel-
oping LVDD or HFpEF.
2. Initial analyses indicate that the HELPFul study popu-
lation has a high prevalence of hypertension, but a low 
prevalence of chronic inflammatory comorbidities that 
are associated with LVDD and HFpEF, such as diabetes 
mellitus and overweight. Furthermore, chest pain is a 
common complaint, hinting towards the importance 
of possible CMD in this study population. The exter-
nal validity could be affected when the generalisability 
to the population at risk of developing LVDD or HF-
pEF in the community is lower. However, hypertension 
and CMD are known to be important in the develop-
ment of LVDD and HFpEF. Therefore, we consider 
the HELPFul study population to be representative of, 
for instance, community-based elderly individuals of 
65 years and older. Even so prudence is appropriate 
when generalising results to community-based or hos-
pital-based patients with LVDD or HFpEF, particularly 
in the context of chronic inflammatory comorbidities.
3. Patients are referred to this centre when the GP con-
siders referral to be indicated. However, the cardiology 
outpatient clinic does not record the indication for re-
ferral in their electronic patient database. Therefore, 
we have no data on the indication for referral. As men-
tioned previously, patients who are referred often do 
not have acute/severe complaints of cardiac problems. 
This could lead to referral bias, which is a form of se-
lection bias usually affecting the comparison of cases 
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and controls and generalisability of the results. Due to 
our study design, we do not expect referral bias to be a 
problem, because cases and participants of the random 
sample are selected from the same source population. 
Furthermore, if future results are generalised within 
the context of the study, we do not see a problem with 
external validity.
In conclusion, HELPFul is an ongoing study recruiting 
men and women at a cardiology outpatient clinic with 
the aim of studying LVDD and HFpEF, that offers unique 
opportunities for well-powered biomarker research in a 
sex-stratified manner.
Ethics and dissemination
The study is conducted according to the principles of the 
Declaration of Helsinki October 2013 and in accordance 
with the Medical Research Involving Human Subjects Act. 
The study does not interfere with routine patient care, 
and all patients will be treated at the discretion of their 
cardiologist or GP according to the appropriate guide-
lines. Participants have given informed consent for extra 
venous blood collection and storage, and for additional 
questionnaires. We will present our findings at national 
and international conferences and in peer-reviewed jour-
nals in cardiovascular disease.
data safety and monitoring board
An independent data and safety monitoring board was 
not installed.
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